Therapeutic use of recombinant methionyl human leptin. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Biochimie Year : 2012

Therapeutic use of recombinant methionyl human leptin.


Recombinant methionyl human leptin (r-metHuLeptin) was first used as a replacement therapy in patients bearing inactivating mutations in the leptin gene. In this indication, it was shown since 1999 to be very efficient in inducing a dramatic weight loss in rare children and adults with severe obesity due to the lack of leptin. These first clinical trials clearly showed that r-metHuLeptin acted centrally to reduce food intake, inducing loss of fat mass, and to correct metabolic alterations, immune and neuroendocrine defects. A few years later, r-metHuLeptin was also shown to reverse the metabolic complications associated with lipodystrophic syndromes, due to primary defects in fat storage, which induce leptin deficiency. The beneficial effects, which could be mediated by central and/or peripheral mechanisms, are thought to mainly involve the lowering effects of leptin on ectopic lipid storage, in particular in liver and muscles, reducing insulin resistance. Interestingly, r-metHuLeptin therapy also reversed the hypothalamic-pituitary-gonadal axis dysfunctions associated with hypothalamic amenorrhea. However, if r-metHuLeptin treatment has been shown to be dramatically efficient in leptin-deficient states, its very limited effect in inducing weight loss in common obese patients revealed that, in patients with adequate leptin secretion, mechanisms of leptin resistance and leptin tolerance prevent r-metHuLeptin from inducing any additional effects. This review will present the current data about the effects of r-metHuLeptin therapy in humans, and discuss the recent perspectives of this therapy in new indications.
Fichier principal
Vignette du fichier
Vatier_et_al_author_final_version.pdf (251.76 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-00848060 , version 1 (25-07-2013)



Camille Vatier, Jean-François Gautier, Corinne Vigouroux. Therapeutic use of recombinant methionyl human leptin.. Biochimie, 2012, 94 (10), pp.2116-25. ⟨10.1016/j.biochi.2012.03.013⟩. ⟨inserm-00848060⟩
307 View
657 Download



Gmail Facebook X LinkedIn More